News Website

Endometriosis Therapeutics Market to Reach US$ 4.05 Billion - openPR.com

Endometriosis Therapeutics Market to Reach US$ 4.05 Billion openPR.com

Published: May 5, 2026, 7:37 a.m.

Read Full Article

Emerging Sub-Segments Transforming the Digital Therapeutics Market for Endometriosis - openPR.com

Emerging Sub-Segments Transforming the Digital Therapeutics Market for Endometriosis openPR.com

Published: May 1, 2026, 1:36 p.m.

Read Full Article

Pathogenesis of Adenomyosis: An Integrated Review of Cellular Origins, Molecular Mechanisms, and Intersecting Diseases.

Adenomyosis is a prevalent disorder of the archimetra, historically conflated with endometriosis but possessing a unique pathobiological trajectory. This review synthesises current molecular evidence to propose a unified mechanistic framework …

Published: April 14, 2026, midnight

Read Full Article

adenomyosis angiogenesis epithelial–mesenchymal transition immune dysfunction stromal–epithelial crosstalk

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers - National Today

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers National Today

Published: April 10, 2026, 4:35 p.m.

Read Full Article

Contemporary Diagnostic and Therapeutic Approaches in Endometriosis: A Systematic Review.

Endometriosis is a chronic inflammatory disorder characterized by pelvic pain, infertility, and reduced quality of life, and is frequently associated with prolonged diagnostic delay and variable treatment response. Although advances …

Published: April 3, 2026, midnight

Read Full Article

biomarkers deep infiltrating endometriosis diagnostic approaches digital therapeutics endometriosis microrna systematic review transvaginal sonography

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Endometriosis Care - The National Law Review

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Endometriosis Care The National Law Review

Published: March 24, 2026, 2:19 p.m.

Read Full Article

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - BioSpace

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis BioSpace

Published: March 23, 2026, 12:47 p.m.

Read Full Article

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - PR Newswire

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis PR Newswire

Published: March 23, 2026, 11:30 a.m.

Read Full Article

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis - Digital Journal

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis Digital Journal

Published: March 18, 2026, 12:41 p.m.

Read Full Article

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis - ACCESS Newswire

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis ACCESS Newswire

Published: March 18, 2026, 10:13 a.m.

Read Full Article

Latest Articles

Endometriosis Therapeutics Market to Reach US$ 4.05 Billion - openPR.com

Emerging Sub-Segments Transforming the Digital Therapeutics Market for Endometriosis - openPR.com

Pathogenesis of Adenomyosis: An Integrated Review of Cellular Origins, Molecular Mechanisms, and Intersecting Diseases.

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers - National Today

Contemporary Diagnostic and Therapeutic Approaches in Endometriosis: A Systematic Review.

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Endometriosis Care - The National Law Review

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - BioSpace

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - PR Newswire

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis - Digital Journal

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis - ACCESS Newswire

Subscribe to Our Newsletter